LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Lista de Ações・Amgen Inc

Amgen Inc

Fechado

SetorSaúde

326.2 -3.03

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

325.13

Máximo

336.3

Indicadores-chave
By Trading Economics
Rendimento	486M 1.8B
Vendas	-1.3B 8.6B
P/E Médio do Setor	22.936 51.415
EPS	5.15
Rendimento de Dividendos	2.91
Margem de lucro	21.107
Funcionários	31,500
EBITDA	-2.3B 2.7B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+8.47% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	2.91% 2.34%
Próximos Ganhos	4 de ago. de 2026
Próxima data de dividendos	5 de jun. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-5.4B 178B
Abertura anterior	329.23
Fecho anterior	326.2

Sentimento de Notícias

By Acuity

32%

68%

81 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

270.44 / 276.44 Suporte e Resistência

Amgen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 20:16 UTC

Ganhos

Amgen Posts Higher 1Q Profit, Revenue

6 de abr. de 2026, 17:09 UTC

Grandes Movimentos do Mercado

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3 de fev. de 2026, 21:49 UTC

Ganhos

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6 de jan. de 2026, 15:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 de nov. de 2025, 21:55 UTC

Grandes Movimentos do Mercado

Amgen Lung Cancer Drug Gets Full Approval From FDA

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen 1Q Adj EPS $5.15 >AMGN

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen 1Q Rev $8.62B >AMGN

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen 1Q Net $1.82B >AMGN

30 de abr. de 2026, 20:01 UTC

Ganhos

Amgen 1Q EPS $3.34 >AMGN

1 de abr. de 2026, 20:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4 de fev. de 2026, 19:56 UTC

Conversa de Mercado

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q Adj EPS $5.29 >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q Net $1.33B >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q Rev $9.9B >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen Sees FY Rev $37B-$38.4B >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3 de fev. de 2026, 21:01 UTC

Ganhos

Amgen 4Q EPS $2.45 >AMGN

28 de jan. de 2026, 17:47 UTC

Ganhos

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6 de jan. de 2026, 14:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 de jan. de 2026, 14:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 de jan. de 2026, 14:00 UTC

Aquisições, Fusões, Aquisições de Empresas

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Comparação entre Pares

Variação de preço

Amgen Inc Previsão

Preço-alvo

By TipRanks

8.47% parte superior

Previsão para 12 meses

Média 364.7 USD 8.47%

Máximo 427 USD

Mínimo 300 USD

Com base em 24 analistas de Wall Street que oferecem metas de preço de 12 meses para Amgen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

24 ratings

Comprar

Manter

Vender

Com base em 24 analistas que deram avaliações de ações para Amgen Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

270.44 / 276.44Suporte e Resistência

Recent bearish events outweigh bullish events.

Sentimento

By Acuity

81 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.